Remove 2027 Remove FDA Remove Insurance
article thumbnail

5 Breo Ellipta savings tips

The Checkup by Singlecare

One example is Breo Ellipta (fluticasone furoate/vilanterol), an inhalation powder approved by the Food and Drug Administration (FDA) as a once-daily maintenance treatment (not a rescue inhaler) for COPD and asthma. Most insurance companies cover some of this drug’s cost. The exact price may vary by location and pharmacy.

article thumbnail

How much does Trulicity cost with Medicare?

The Checkup by Singlecare

Currently, there is no generic version of Trulicity that’s FDA -approved. If you are on Medicare for health insurance , you might wonder: Does Medicare cover Trulicity ? The rules vary by plan, so I usually recommend checking with your insurance or having your pharmacist look it up for you,” he says.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Piramal Pharma announces $90m investment to expand US sites

Pharmaceutical Technology

The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. The expansion will introduce a new laboratory and advanced machinery such as a new filling line, two large size lyophilisers, a capping machine and an external vial washer.

article thumbnail

Merck concludes SpringWorks acquisition for $3.4bn

Pharmaceutical Technology

The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) also recommended its approval in June 2025.

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.

FDA 52
article thumbnail

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

An injectable version of lenacapavir given twice a year was approved by the US Food and Drug Administration (FDA) last month, licensed as a pre-exposure prophylaxis (PrEP) option for HIV prevention. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. Sign up for our daily news round-up!

article thumbnail

Sanofi agrees to invest $25m in Adagene

Pharmaceutical Technology

With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m. Give your business an edge with our leading industry insights.